Johnson & Johnson Pharmaceuticals SARS-CoV-2 coronavirus vaccine elicited a “long-lasting” immune response, according to an initial safety study.
According to the newspaper El Financiero, more than 90 percent of the volunteers produced immune proteins after receiving the only injection within 29 days after it.
Those results are from the phase 1/2 trial of 805 participants aged 18 and over that were published Wednesday in the New England Journal of Medicine.
The progress of the pharmaceutical company biological is being monitored by experts since it is the vaccine with the potential to be the first to protect people with a single dose, facilitating campaigns.
In turn, the company expects to have definitive results of the final study in the first days of February, which could be authorized by March.